Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)
This study is investigating a medicine called Cosentyx (secukinumab) for adults who have a long-lasting sinus condition with nasal polyps, often called Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), but not specifically linked to type 2 inflammation. If you've been living with stuffy noses, facial pain, and a reduced sense of smell because of nasal polyps, and other treatments haven't given you enough relief, this study might be relevant. Researchers want to see if Cosentyx can significantly improve these symptoms and reduce the size of the polyps. This is a Phase 4 study, meaning the drug is already approved for other conditions, and now researchers are looking at its use for this specific type of CRSwNP in a real-world setting.
At a glance
What is this study about?
This study is focused on a long-term condition called Chronic Rhinosinusitis with Nasal Polyps, or CRSwNP for short. Imagine having a stuffy nose that just won't clear, facial pain, pressure, and a reduced sense of smell, all caused by soft, grape-like growths inside your nose called nasal polyps. For many people, these symptoms are ongoing and can really affect daily life.
The specific type of CRSwNP being studied here isn't the 'type 2' kind, which is driven by a particular type of immune response. This means that people whose CRSwNP doesn't fit the 'type 2' profile, and who might not have responded well to other treatments, are the focus. The medicine being tested is called Cosentyx (its scientific name is secukinumab). It's a type of drug that works by targeting a specific part of your immune system to help reduce inflammation. By understanding how Cosentyx works for this specific group, doctors hope to find better ways to manage this challenging condition.
The main goal of the study is to see if Cosentyx can make a noticeable difference in your nasal polyp symptoms and how you feel generally. They will measure changes in your nasal polyps and how much your overall symptoms bothered you after 16 weeks. They'll also look at how Cosentyx might affect certain inflammation markers in your body, to better understand how it works.
Key takeaways
- The study explores Cosentyx for chronic sinus issues with nasal polyps.
- It targets adults whose condition isn't 'type 2' and hasn't responded to other treatments.
- The main aim is to see if Cosentyx improves symptoms and reduces polyps over 16 weeks.
- Participation involves regular clinic visits and injections of the study drug.
- You'll be closely monitored for health changes and potential side effects.
- Voluntary participation means you can withdraw at any time without penalty.
Who may be eligible?
To be considered for this study, you need to be an adult, age 18 or older. Both men and women can take part. The study is specifically for people who have Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) that doctors don't classify as 'type 2' inflammation.
This means you would likely have ongoing symptoms like a stuffed-up nose, facial pain, and a decreased sense of smell because of nasal polyps. Importantly, the study is for people whose current treatments haven't been fully effective in controlling their symptoms.
There will be other detailed health requirements that your study doctor will discuss with you. These are in place to make sure the study is safe for you and that the results will be clear and reliable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have long-lasting sinus problems with nasal polyps?
- Has your doctor told you your condition is NOT 'type 2' CRSwNP?
- Have other treatments for your nasal polyps not worked well enough?
- Are you able to attend regular clinic visits for 16 weeks?
What does participation involve?
If you decide to take part in this study, you would receive the study medicine, Cosentyx, as an injection. This is given using a pre-filled syringe. You would have regular visits to the study clinic over a period of 16 weeks. At these visits, doctors and nurses would check your health, ask about your symptoms (like how stuffy your nose feels and how your sense of smell is), and examine your nasal polyps.
They would also take blood samples to look at your general health and how the medicine might be affecting inflammation markers. Throughout the study, you'd be closely monitored for any changes or side effects. The total duration for your active participation, receiving treatment and having assessments, would be 16 weeks, followed by any necessary follow-up.
Potential risks and benefits
Locations (1)
- —UnverifiedEstonia
Common questions
What are nasal polyps?
Nasal polyps are soft, painless, non-cancerous growths that form in the lining of your nose or sinuses. They can cause a stuffy nose, reduced sense of smell, and other symptoms.
What is Cosentyx?
Cosentyx is a medicine given by injection that works by targeting a specific part of your immune system. It is approved for other conditions and is being studied here for a type of chronic sinus problem.
How long will I be in the study?
If you join, the main treatment and assessment period will be 16 weeks, with potential follow-up after that.
Will I have to pay to be in the study?
No, all study-related treatments and assessments are provided at no cost to you.
Can I stop participating if I want to?
Yes, you have the right to leave the study at any time, for any reason, and it will not affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.